A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI greater than or equal to 35.

Trial Profile

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI greater than or equal to 35.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms EQUIP
  • Sponsors VIVUS
  • Most Recent Events

    • 28 Apr 2017 Results (n=3040) assessing efficacy and safety of phentermine/topiramate extended release for weight loss in overweight and obese patients using pooled data from CONQUER, EQUIP and SEQUEL trials, published in the Diabetes Care
    • 03 Nov 2011 Results published in the Obesity (Silver Spring, Md.).
    • 03 Nov 2011 Results published in Obesity, according to a VIVUS media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top